Key Details
Price
$0.96Last Dividend
$1.10Annual Revenue
$56.83 MAnnual EPS
-$3.20Annual ROE
100.29%Beta
-0.87Events Calendar
Next earnings date:
Apr 04, 2025Recent quarterly earnings:
Nov 15, 2024Recent annual earnings:
Apr 04, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
June 05, 2015Next split:
N/ARecent split:
Feb 23, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology.
DUBLIN, Ireland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from the World Health Organization (WHO) to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at its outsourced provider. This approval was a key prerequisite in the manufacturing transfer the Company has been working towards as part of its Comprehensive Transformation Plan.
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025 Reiterates guidance to achieve 2024 sales revenue for TrinScreen HIV of approximately $10 million DUBLIN, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company's results for the quarter ended September 30, 2024. Key Highlights and Developments Continued Revenue and Profitability Improvements Year-over-year revenue growth of 3% and continued disciplined execution on our profitability enhancing initiatives contributed to a decrease in the operating loss (before restructuring and impairment charges) to $2.2 million from $4.5m in Q3 2023, a 51% improvement.
Trinity Biotech Plc (NASDAQ:TRIB ) Q3 2024 Earnings Conference Call November 15, 2024 10:00 AM ET Company Participants Eric Ribner - Investor Relations John Gillard – President, Chief Executive Officer Louise Tallon - Chief Financial Officer Conference Call Participants James Sidoti - Sidoti & Company Paul Nouri – Noble Equity Funds Operator Greetings. Welcome to the Trinity Biotech Third Quarter 2024 Earnings Conference Call.
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company pioneering a rapid sepsis testing platform. This investment will accelerate the development and commercialization of Novus' groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infection test.
TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.
DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technology from Waveform Technologies in January 2024.
TRIB acquires Metabolomics Diagnostics, expanding its platform with cutting-edge tech to enhance diagnostics in maternal health and diabetes management.
-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women-
TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.
FAQ
- What is the primary business of Trinity Biotech?
- What is the ticker symbol for Trinity Biotech?
- Does Trinity Biotech pay dividends?
- What sector is Trinity Biotech in?
- What industry is Trinity Biotech in?
- What country is Trinity Biotech based in?
- When did Trinity Biotech go public?
- Is Trinity Biotech in the S&P 500?
- Is Trinity Biotech in the NASDAQ 100?
- Is Trinity Biotech in the Dow Jones?
- When was Trinity Biotech's last earnings report?
- When does Trinity Biotech report earnings?
- Should I buy Trinity Biotech stock now?